MedTrace Logo

Quadruple vs Tailored Therapy in the Treatment of Helicobacter Pylori Infection

NCT04621487 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-11-09

No results posted yet for this study

Summary

Non-bismuth quadruple therapies have been proposed as potential strategies in improving the efficacy of first-line treatments. The non-bismuth quadruple therapy in its concomitant variant consists of proton pump inhibitor, amoxicillin, nitroimidazole and clarithromycin given concurrently twice daily. As a result of concurrent administration this therapy has given better results according to some studies in comparison to sequential variants. However, this therapy, as well suffers from the aforementioned increase in antibiotic resistance. Therefore, the aim of this study was to compare concomitant non-bismuth quadruple therapy with a tailored therapy based on antibiotic strain susceptibility testing.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Amoxicillin

14 days 1 gr bid

DRUG

Metronidazole

14 days 500 mg bid

DRUG

Clarithromycin

14 days 500 mg bid

DRUG

Pantoprazole 40mg

40 mg bid 14 days

DRUG

according to antibiogram

according to antibiogram

Sponsors & Collaborators

  • University of Split, School of Medicine

    lead OTHER

Principal Investigators

  • Nikola Perkovic, MD · University hospital Split

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2020-01-15
Completion
2020-02-15

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04621487 on ClinicalTrials.gov